X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-01-15 | GBIO | Angelino Mark D. | COO | S - Sale+OE | $32.97 | -7,500 | 515,483 | -1% | -$247,273 | |||||
| D | 2021-01-14 | GBIO | Zimmermann Tracy | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $33.09 | -2,500 | 0 | -100% | -$82,725 | |||||
| D | 2021-01-14 | GBIO | Stanton Matthew | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $32.54 | -5,630 | 198,154 | -3% | -$183,212 | |||||
| D | 2021-01-11 | GBIO | Kerr Douglas | CHIEF MEDICAL OFFICER | S - Sale+OE | $27.58 | -11,267 | 326,558 | -3% | -$310,768 | |||||
| D | 2021-01-11 | GBIO | Stanton Matthew | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $27.69 | -14,820 | 198,154 | -7% | -$410,372 | |||||
2021-01-11 | GBIO | Nicholson Donald William | Dir | P - Purchase | $24.50 | +4,081 | 103,157 | +4% | +$99,985 | ||||||
2021-01-11 | GBIO | Rowland Charles A Jr | Dir | P - Purchase | $24.50 | +20,408 | 101,035 | +25% | +$499,996 | ||||||
| D | 2020-12-15 | GBIO | Angelino Mark D. | COO | S - Sale+OE | $34.98 | -5,301 | 515,483 | -1% | -$185,431 | |||||
| D | 2020-12-10 | GBIO | Stanton Matthew | Chief Scientific Officer | S - Sale+OE | $37.62 | -10,540 | 198,154 | -5% | -$396,499 | |||||
| D | 2020-06-16 | GBIO | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% | P - Purchase | $19.00 | +1,100,000 | 2,112,546 | +109% | +$20,900,000 | |||||
| D | 2020-06-16 | GBIO | Invus Public Equities, L.P. | 10% | P - Purchase | $19.00 | +800,000 | 2,814,191 | +40% | +$15,200,000 | |||||
| D | 2020-06-16 | GBIO | Rowland Charles A Jr | Dir | P - Purchase | $19.00 | +30,000 | 80,627 | +59% | +$570,000 | |||||
| D | 2020-06-16 | GBIO | Casdin Capital, LLC | 10% | P - Purchase | $19.00 | +650,000 | 1,611,215 | +68% | +$12,350,000 | |||||
| D | 2020-06-16 | GBIO | Zone Healthcare Holdings, LLC | Member of Group Owning 10%, 10% | P - Purchase | $19.00 | +400,000 | 5,356,457 | +8% | +$7,600,000 | |||||
| D | 2020-06-16 | GBIO | Seybold William | Member of Group Owning 10%, 10% | P - Purchase | $19.00 | +400,000 | 5,356,457 | +8% | +$7,600,000 | |||||
| D | 2020-06-16 | GBIO | Flynn James E | Possible Member of 10% Group, 10% | P - Purchase | $19.00 | +225,000 | 1,186,215 | +23% | +$4,275,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |